Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35142582/
In multiple myeloma (MM), it is unclear whether early and late responders to daratumumab have similar outcomes. We pooled individual-level data from phase 3 trials and divided them into early...
Conclusion: These results support that for patients who failed to achieve an early response to daratumumab, therapies should be continued with the goal of achieving ongoing and stepwise improvement of response.
Activity of Decitabine as Maintenance Therapy in Core Binding Factor Acute Myeloid Leukemia
Source : https://onlinelibrary.wiley.com/doi/10.1002/ajh.26496
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between...
Conclusion: Decitabine is an effective maintenance therapy for CBF-AML patients with persistent fusion transcript at a low level after FLAG based regimen. Attainment of CMR with DAC maintenance can lead to long term remission in patients who have persistent MRD positive after FLAG based regimen or are unable to receive the full course of...
Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35093506/
doi: 10.1016/j.trim.2022.101544. Online ahead of print. 1 Georgia Cancer Center at Augusta University, Augusta, GA, United States of America. Electronic address: [email protected]. 2 Department of Hematology/Oncology, University of Oklahoma, Oklahoma...
Conclusion: We conclude that for multiple myeloma patients treated with ASCT, high absolute NK cell counts two to three months after ASCT is an independent predictor for MRD negativity.
Prognostic significance of IKZF1 deletions and IKZF1plus profile in children with B‐cell precursor acute lymphoblastic leukemia treated according to the ALL‐IC BFM 2009 protocol
Source : https://onlinelibrary.wiley.com/doi/10.1002/hon.2973
Corresponding Author Marcin Braun Department of Pathology, Chair of Oncology, Medical University of Lodz, Poland Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Poland equal contribution Correspondence Agata...
Conclusion/Relevance: Both genetic markers including IKZF1del and IKZF1plus microdeletion profile provide additional predictive value of treatment outcome in childhood BCP-ALL and may contribute to more efficient patient stratification; the same is true in MRD guided protocols, which are based on flow cytometric measurements on day 15 of...
The role of minimal residual disease in chronic lymphocytic leukemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35120090/
Minimal residual disease (MRD) has evolved as a sensitive and highly prognostic surrogate parameter of response to therapy in chronic lymphocytic leukemia (CLL). Multiple methods have been established to measure...
Conclusion/Relevance: In this review, we summarize currently available methods of MRD detection, provide recent MRD data and outcomes from clinical trials in CLL, and discuss open questions and future approaches for MRD within and outside clinical trials.